-20 at 5% false discovery rate) and 51 species in the population 36 samples (p-value range 0.017-6.8*10 -21 ). Hypertriglyceridemia was associated with altered levels of 37 117 lipid species in families (p-value range 0.035-1.8*10
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47
High levels of low-density lipoprotein cholesterol (LDL-C) and triacylglycerides (TGs) have been 48 identified as causal risk factors for atherosclerotic cardiovascular disease (ASCVD).
1, 2 These 49 hyperlipidemias may arise through lifestyle factors, but they are also highly heritable.
3-6 More than half 50 of patients with premature coronary artery disease (CAD) may be affected by familial dyslipidemias, a 51 majority of which are characterized by elevations in LDL-C and/or TGs. 
52
Whether familial hyperlipidemias should be diagnosed and managed differently from 53 hyperlipidemias observed in randomly ascertained individuals in the general population is uncertain. 54
Carriers of rare high-impact variants predisposing to familial hypercholesterolemia (FH) may have a 55
higher risk of developing coronary artery disease than non-carriers with similar lipid levels.
8 This is 56 potentially related to lifelong exposure to high LDL-C levels and suggests that these individuals may 57 benefit from earlier or more aggressive LDL-C-lowering therapy. 58
Rare variants, however, explain only a small fraction of familial hyperlipidemias with either 59 elevated LDL-C or TG levels. Instead, there is growing evidence that familial hyperlipidemias are highly 60 polygenic in origin. [8] [9] [10] [11] [12] [13] It is of high clinical importance whether non-monogenic familial hyperlipidemias 61 represent distinct disease entities and lead to different ASCVD susceptibility compared with population-62 ascertained hyperlipidemias.
14 A recent study provided suggestive evidence to the contrary, finding 63 greater preclinical atherosclerosis in monogenic FH than in polygenic hypercholesterolemia.
15 However, 64 it is unknown how these results translate to clinical outcomes between familial and population-65 ascertained hyperlipidemias. 66
How the heterogenic genetic background of familial hyperlipidemias manifests in detailed 67 circulating lipid profiles, and reflects underlying pathophysiology, is also unknown. Recent 68 technological advancements have allowed replicable and simultaneous quantification of hundreds of 69 lipid species through lipidomic profiling. 16, 17 We tested whether precise phenotypic differences in 70 lipidomic profiles, which might underlie differing ASCVD susceptibility, exist between familial and 71 population-ascertained hyperlipidemias after excluding individuals with monogenic FH. We looked 72 beyond the traditional clinical measures of LDL-C and TG concentrations at the numerous fatty acid 73 ester species of TGs and cholesterol species which are the major constituents of LDL and TG-rich 74 lipoprotein particles. We used a direct infusion platform that combines absolute quantification with high 75 throughput, overcoming problems that have hampered many previous studies.
18
76
Lipid species including sphingolipids, glycerophospholipids, glycerolipids and cholesteryl 77 esters may predict ASCVD incidence or event risk over traditional risk factors, and the levels of many 78 individual lipid species have been linked to distinct genetic loci.
19-22 Major differences in the metabolic 79 pathways underlying different types of hyperlipidemias would thus be expected to be reflected in 80 different lipidomic profiles. As an example, individuals with low HDL-C levels have previously been 81 shown to have low phosphatidylethanolamine-plasmalogen levels in HDL particles, a marker of HDL 82
anti-oxidative capacity.
23
83
In the present study, we first estimated the CAD risk associated with familial and population-84 ascertained hyperlipidemias. Secondly, we characterized the lipidomic profiles associated with elevated 85 plasma levels of LDL-C and TGs. Finally, we compared the lipidomic profiles of familial and 86 population-ascertained hyperlipidemias to assess their potential differences. 87
Materials and Methods
88
Subjects and clinical ascertainment 89
The Finnish hyperlipidemia families included in this cohort study (74 families, n = 1,445 individuals 90 with at least LDL-C and TG measures) were identified as part of The European Multicenter Study on 91
Familial Dyslipidemias in Patients with Premature Coronary Heart Disease (EUFAM). Designation of 92 "familial high LDL-C" or "familial high TGs" was made if at least two first-degree relatives of each 93 other had LDL-C or TG levels, respectively, that were > 90 th age-and sex-specific Finnish 1997 94 population percentiles (Supplemental Table IV 
Lipidomics measurements 105
Lipidomic profiling and analysis of circulating lipid species was performed for 550 EUFAM family 106 members with available plasma samples and for 897 individuals from the FINRISK 2012 cohort. Mass 107 spectrometry-based lipid analysis was performed at Lipotype GmbH (Dresden, Germany) as 108
described.
16 Plasma and serum lipids were extracted with methyl tert-butyl ether/methanol (7:2, V:V) 109 as in Matyash et al. 24 Samples were analyzed by direct infusion in a QExactive mass spectrometer 110 (Thermo Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Samples 111 were analyzed in both positive and negative ion modes in a single acquisition. 112
Data were analyzed with in-house developed lipid identification software based on 113
LipidXplorer. 25, 26 Reproducibility was assessed by the inclusion of reference plasma samples. Median 114 coefficient of variation was <10% across all batches. A total of 151 species were detected in ≥ 80% of 115 both EUFAM and FINRISK samples and were included in the subsequent analyses. Right-skewed 116 lipidomics measures were natural logarithm transformed prior to normalization by standard deviation. 117
More detailed information is given in the Supplementary material online. 118
Statistical analyses 119
To assess the risk of incident coronary artery disease associated with the hyperlipidemias, we used Cox 120 proportional hazards models using age as the time scale, stratified by sex, and clustered by family to 121 estimate hazard ratios (HR) for incident CAD events, excluding individuals with prevalent CAD. Figure I .A.). Individuals with high LDL-C had an increased risk of being diagnosed with 136 CAD in the FINRISK population surveys (n = 19,644 individuals) compared to other individuals (HR 137 1.74; 95% CI 1.48-2.05). The members of hyperlipidemic families with high LDL-C had a similar 138 though nonsignificant HR compared to their relatives without high LDL-C in 47 "high LDL-C" families 139 (n = 633 individuals) (HR 1.71; 95% CI 0.94-3.10). The HRs did not differ between the cohorts 140 (p=0.60). We also observed an increased CAD risk in individuals with high TGs in the population (HR 141 1.38; 95% CI 1.08-1.75), and a similar though nonsignificant HR in 35 "high TG" families (n = 375 142 individuals) (HR 1.35; 95% CI 0.52-3.51). The HRs did not differ between the cohorts (p=0.91). Meta-143 analyses of HRs closely approximated estimates derived in the population cohort. 144
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We then characterized the detailed lipidomic profiles of 550 individuals from 73 hyperlipidemic 146 families and 897 individuals from the FINRISK population study (Methods; Supplemental Table II ; 147
Supplemental Figure I.B.). These included 105 individuals (23 %) out of 463 family members in 53 148
"high LDL-C" families who had LDL-C levels >90 th percentile (mean ± SE 5.2 ± 0.8 mmol/l), and 64 149 individuals (22 %) out of 287 family members in 39 "high TG" families who had TGs >90 th percentile 150 (3.6 ± 2.0 mmol/l). Using similar cutoffs in the population, 56 individuals (6 %) and 65 individuals (7 151 %) out of 897 individuals were affected by high LDL-C levels (5.3 ± 1.1 mmol/l) and high TGs (3.5 ± 152
1.6 mmol/l) respectively. Simultaneously high LDL-C and TG levels were observed in 31 individuals 153 in the family samples and 9 individuals in the population samples. 154
High LDL-C and lipidomic profiles 155
To characterize the lipidomic profiles associated with elevated values of LDL-C, we compared 156 individuals with high LDL-C levels vs. those without. In the hyperlipidemic families, individuals with 157 high LDL-C had significantly elevated levels of 99 lipid species spread out across most of the studied 158 lipid classes. Reduced levels were observed for three lysophospatidylcholine (LPC), two 159 lysophosphatidylethanolamine (LPE) and one phosphatidylcholine-ether (PCO) species ( Figure 1 .A.; 160 Supplemental Table III) . Similar trends were seen in the population when comparing individuals with 161 high LDL-C vs. those without. We observed significantly elevated levels of 51 lipid species ( Figure  162 1.B.; Supplemental Table III ). The effect estimates correlated strongly across all lipid species between 163 the hyperlipidemic families and the population cohorts (Pearson's r = 0.80; Figure 3 ). Further, we 164 observed no statistically significant cohort-dyslipidemia interactions at the 5% false discovery rate. 165
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We also studied the association of high LDL-C levels with the degree of saturation of fatty acids 167 in each lipid class. In the hyperlipidemic families, high LDL-C levels were associated with increased 168 saturation of LPCs and ceramides, as well as reduced saturation of LPEs, PCs, phosphatidylcholine-169 ethers (PCOs), and phosphatidylinositols (PIs) (p-value range = 0.019-0.0014) (Supplemental Figure  170 II). In the population samples, the trends were similar, although there was an association for increased 171 LPC saturation only (p=7.2*10 -4 ). There were no cohort-hyperlipidemia interactions in any of the lipid 172 species at the 5% false discovery rate. Overall, the lipidomic profiles associated with high LDL-C levels 173 appeared similar in the hyperlipidemic families and the general population. 174
High TGs and lipidomic profiles 175
In the hyperlipidemic families, individuals with high TGs had elevated levels of 107 lipid species 176 covering all studied lipid classes with the exception of LPEs. In addition, we observed reduced levels 177 of seven PCO, two LPC, and one PI species (Figure 2 .A.; Supplemental Table III) . Similar profiles were 178 seen in the population when comparing individuals with high TGs vs. those without. We observed 179 elevated levels of 108 species and reduced levels of ten PCO and one LPC species (Figure 2 .B.; 180
Supplemental Table III ). The effect estimates correlated very highly across all species between families 181 and population samples (Pearson's r = 0.96; Figure 3 ). Further, we observed no cohort-dyslipidemia 182 interactions for any of the lipid species at the 5% false discovery rate. 183
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Next, we studied the association of high TG levels with the degree of saturation of fatty acids in each 186 lipid class. In both the hyperlipidemic families and the population, having high TGs was significantly 187 associated with increased saturation of TGs, DGs, LPCs, and CEs (p-value range = 0.0012-5.9*10 -11 ) 188 (Supplemental Figure III ). There were no statistically significant cohort-hyperlipidemia interactions at 189 the 5% false discovery rate. Overall, we observed great similarity in the lipidomic profiles associated 190 with high TGs in the hyperlipidemic families and in the general population. 191
Independent associations of LDL-C and TG values with the lipid species 192
Since we observed modest combined hyperlipidemia in both cohorts, we estimated the independent 193 associations of LDL-C and TGs with each lipid species in co-adjusted models (Figure 4 ; Supplemental 194 Table III) . In these analyses, many of the observed associations with LDL-C were greatly diluted in 195 magnitude. LDL-C levels remained most strongly associated with CE, SM, ceramide, PC and PCO 196 species in both cohorts. A total of 83 species in the hyperlipidemic families and 91 species in the 197 population were independently associated with LDL-C at the 5% false discovery rate. In contrast, TGs 198 remained strongly associated with a wide range of lipid species, including all individual TG species, 199
DGs, PCs, PEs, PIs, ceramides and a subset of CEs in both cohorts. A total of 125 species in the 200 hyperlipidemic families and 124 species in the population were independently associated with TGs at 201 the 5% false discovery rate. Overall, only 13 species were uniquely associated with LDL-C in either 202 cohort, whereas 42 species were uniquely associated with TGs (Supplemental Figure IV) . 203
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Discussion
205
Recent lipidomic approaches have identified several hundreds of different lipid species in the human 206 circulation, some of which could be better prognostic biomarkers for atherosclerotic cardiovascular 207 disease than the traditional clinical chemistry measurements. To the best of our knowledge, the present 208 study is the most comprehensive lipidomic profiling of common hyperlipidemias to date. We used a 209 mass spectrometric lipidomics platform to assess the lipidomic profiles in individuals with high LDL-C 210 and/or TG levels. We found that individuals affected by high levels of LDL-C or TGs had CAD HRs 211 between 1.34-1.74 in the family and population cohorts and exhibited distinct lipidomic profiles with 212 clear variation between lipid classes. In total, out of 151 lipidomic species, 108 were significantly 213 associated with high LDL-C and 131 with high TG levels in at least one cohort. Of these, 96 species 214 were common with both high LDL-C and TGs. In addition, we observed highly similar lipidomic 215 profiles between the familial and population-ascertained hyperlipidemias. 216
These findings allow us to draw several conclusions. First, the CAD risks are highly similar 217 regardless of whether hyperlipidemic individuals were identified from families with a high prevalence 218 of hyperlipidemia or from the general population. This result contrasts with earlier results reporting 219 much higher CAD risks in relatives of familial combined hyperlipidemia probands compared to 220 spouses.
29 Our study, however, compares the estimates between family members to individuals with 221 closely similar lipid levels from the population to isolate the effect of familiality. We also study the risk 222 associated with elevated LDL-C and TGs separately. Our estimates are also lower than typically reported 223 for monogenic FH, which may be associated with lifelong exposure to very high LDL-C levels and 224 increased CAD risk compared with other individuals with similarly extreme hyperlipidemias.
8 In the 225 present study, we excluded probands with monogenic FH based on a functional LDL receptor test. 226
Excepting monogenic FH, familial hyperlipidemias with high LDL-C and/or TG levels have been 227 reported to be highly polygenic.
9, 10, 13, 30 The pleiotropic effects of diverse genes, in contrast with the 228 single affected pathway in monogenic FH, may partly explain why we did not observe increased CAD 229 risk due to familiality in our study. 230
Second, to more deeply characterize potential differences between familial and population-231 ascertained hyperlipidemias, we performed precise phenotyping of circulating lipid species known to 232 be associated with ASCVD risk. [20] [21] [22] We first characterized the lipid profiles associated with high LDL-233 C and TG levels. Many of the associations were not specific to LDL-C but rather due to combined 234 dyslipidemia. LDL particles are generated in circulation as downstream metabolic products from the 235 34 However, in our study, PCs were overall more strongly 243 associated with TG levels than with LDL-C levels. Nevertheless, LDL-C remained positively associated 244 with a range of species including CEs, ceramides, SMs, PCs and PCOs. Among the strongly increased 245 species, CE(14:0), CE(16:0), CE(16:1), CE(18:0), SM(34:1;2), SM(34:2;2), SM(42:2;2), Cer(42:1;2), 246
and Cer(42:2;2) have previously been associated with the risk of future ASCVD incidence or events. 
248
Elevated TG levels were associated with either increases or decreases in the levels of lipid 249 species across most classes. Importantly, most of these associations appeared to be independent of LDL-250 C levels. Among the lipid species that were strongly correlated with high TGs even after correction for 251 LDL-C levels were several species which have previously been associated with risk of ASCVD 252 incidence or events. Further, high TGs were associated with increased saturation of fatty acids in the TG, DG, CE and LPC 255 classes. Such differences in the relative concentrations of circulating fatty acids can be partly related to 256 dietary intake, but are also influenced by endogenous metabolism.
257
Overall, a larger proportion of the lipid species previously linked with increased ASCVD risk 258
were strongly associated with elevated TGs rather than with elevated LDL-C. This interesting 259 observation suggests that the levels of these lipid biomarkers are more closely linked with circulating 260
TG-rich lipoprotein metabolism than with low-density lipoproteins. 261
Third, several lipid species, such as specific cholesteryl esters, ceramides, and 262 phosphatidylcholine-ethers, remained independently associated with both elevated LDL-C and TGs. 263
Among these species, the ceramides Cer(42:1;2) (presumably Cer(d18:1/24:0)) and Cer(42:2;2) 264 (presumably Cer(d18:1/24:1)), the sterol esters CE(16:1) and CE(18:0), and the sphingomyelin 265 SM(34:1;2) may have added value in the prediction of ASCVD incidence or event risk over traditional 266 lipid measurements.
20-22 Plasma ceramides have been reported to be independent predictors of 267 cardiovascular events in addition to LDL-C in the population and in CAD patients.
22, 36, 37 Both LDL-C 268 and TGs remained independently associated with all four ceramides quantified in our study, and LDL-269 C was additionally associated with increased saturation degree of ceramides. Unlike most CE species, 270 CE(16:1) was more strongly associated with the concentration of TGs than with LDL-C concentration 271 in our study. SM(34:1;2) was the only sphingomyelin species which was negatively associated with TGs 272 -and this association became evident only after adjusting for LDL-C levels. Additionally, some species, 273 such as Cer(42:1;2) and TG(56:6), which were positively associated with hyperlipidemias in our sample, 274 have previously been reported to be associated with decreased risk of ASCVD events.
20, 22 These co-275 associations and discordances between reported associations might explain why some lipid species can 276 improve risk prediction. Consequently, there is an urgent need for a better understanding of the potential 277 underlying signaling and metabolic pathways. 278
Finally, the lipidomic profiles associated with high LDL-C or TG levels were comparable 279 between familial and population-ascertained hyperlipidemias. We observed no differences in either the 280 levels of individual lipid species or the saturation of fatty acids within lipid classes. Our results support 281 the hypothesis that familial and population-ascertained hyperlipidemias have similar, overlapping, and 282 heterogeneous pathophysiology. Our results are also reassuring for the quality of lipidomics studies 283 which combine familial and population-based hyperlipidemic samples to increase statistical power. 284
Although we present the most comprehensive characterization of coronary artery disease risk 285 and circulating lipid species in common familial hyperlipidemias to date, our study has some limitations. 286
The confidence intervals for CAD risk were relatively large in the family samples. The field of 287 lipidomics is still relatively young, and concerns have been raised regarding the replicability of 288 individual lipidomics platforms. The platform used here overcomes these problems by profiting from 289 the advantages of direct infusion mass spectrometry for high throughput screening studies. We also 290 observed similar lipidomic profiles associated with hyperlipidemia in two independent cohorts, 291 supporting the replicability of the platform. Further, the lipid species included in our analyses are 292 strongly associated with known genetic lipid loci (Supplemental Figures V-VIII) . We profiled the whole 293 circulating lipidome at once to capture variation across various lipoprotein classes and size distributions. 294
However, this limits our ability to follow up on observed differences at the level of the individual 295 lipoproteins. We excluded poorly captured lipid species from the analyses; future advances in lipidomics 296 technology might enable their detection. It is unclear how well our results can be generalized to other 297 populations than Finns. Some of the individuals surveyed in population cohorts might in fact have 298 familial hyperlipidemia; we could not fully rule out such cases. As this was a cross-sectional study, 299
single LDL-C and TG measurements were used to establish hypercholesterolemia status. However, 300 especially TGs are known to exhibit diurnal variability-especially in relation to dietary episodes with 301 chylomicron entry-as well as variation over time periods of months to years. [38] [39] [40] In this study, the 302 samples from the hyperlipidemic families were fasting and the samples from the population cohort were 303 semi-fasting. In this light, the similarity of lipidomic profiles between familial and population-304 ascertained hypertriglyceridemias becomes even more striking. Moreover, the most recent consensus 305 statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry 306
and Laboratory Medicine recommends routine use of non-fasting blood samples for assessment of 307 plasma lipid profiles.
41
308
In conclusion, we observed distinct lipidomic profiles associated with high levels of LDL-C and 309
TGs, but similar CAD risk and lipidomic profiles between common familial and population-ascertained 310 hyperlipidemias, providing further evidence of similar and overlapping underlying mechanisms. The 311 high degree of similarity between these familial dyslipidemic individuals and random population 312 samples in their genomic and lipidomic profiles, and in elevated CAD risk, does not support different 313 screening and treatment for familial and sporadic cases. Additional work is needed to confirm the 314 validity of this hypothesis in clinical settings. 315 analysis, decision to publish, or preparation of the manuscript. 331
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